Mylan Reaffirms Commitment To Brand Business Growth Despite King Setback

The company will continue to explore acquisition opportunities, CEO Coury says, noting King was not "the only option." Mylan is not yet discussing whether it will launch and market nebivolol on its own or seek a partner for the cardiovascular agent; J&J holds a "right to consent" to any partner.